Oncology Institute Inc (NASDAQ:TOI)’s traded shares stood at 0.29 million during the last session, with the company’s beta value hitting 0.72. At the close of trading, the stock’s price was $1.58, to imply a decrease of -14.13% or -$0.26 in intraday trading. The TOI share’s 52-week high remains $2.65, putting it -67.72% down since that peak but still an impressive 79.11% since price per share fell to its 52-week low of $0.33. The company has a valuation of $116.53M, with an average of 0.19 million shares in intraday trading volume over the past 10 days and average of 137.18K shares over the past 3 months.
Oncology Institute Inc (NASDAQ:TOI) trade information
After registering a -14.13% downside in the last session, Oncology Institute Inc (TOI) has traded red over the past five days. The stock hit a weekly high of 1.8900, dropping -14.13% in its intraday price action. The 5-day price performance for the stock is 16.18%, and -14.59% over 30 days. With these gigs, the year-to-date price performance is -22.55%. Short interest in Oncology Institute Inc (NASDAQ:TOI) saw shorts transact 0.23 million shares and set a 2.11 days time to cover.
Oncology Institute Inc (TOI) estimates and forecasts
Looking at statistics comparing Oncology Institute Inc share performance against respective industry, we note that the company has outperformed competitors. Oncology Institute Inc (TOI) shares are 6.76% up over the last 6 months, with its year-to-date growth rate higher than industry average at 43.48% against 14.10%. The rating firms project that company’s revenue will grow 28.40% compared to the previous financial year.
Revenue forecast for the current quarter as set by 1 analysts is $85.79 million. Meanwhile, for the quarter ending Mar 2024, a total of 1 analyst(s) estimate revenue growth to $85 million.Earnings reports from the last fiscal year show that sales brought in $71.42 million and $76.19 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 20.10% before jumping 11.60% in the following quarter.
TOI Dividends
Oncology Institute Inc has its next earnings report out between March 07 and March 11. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Oncology Institute Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Oncology Institute Inc (NASDAQ:TOI)’s Major holders
Oncology Institute Inc insiders hold 19.86% of total outstanding shares, with institutional holders owning 57.96% of the shares at 72.33% float percentage. In total, 57.96% institutions holds shares in the company, led by FMR, LLC. As of Jun 29, 2023, the company held over 4.75 million shares (or 6.52% of shares), all amounting to roughly $2.62 million.
The next major institution holding the largest number of shares is Deerfield Management Company, L.P. (Series C) with 3.36 million shares, or about 4.61% of shares outstanding. As of the market price on Jun 29, 2023, these shares were worth $1.85 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Oncology Institute Inc (TOI) shares. Going by data provided on Jun 29, 2023, Vanguard Total Stock Market Index Fund holds roughly 1.27 million shares. This is just over 1.75% of the total shares, with a market valuation of $0.7 million. Data from the same date shows that the other fund manager holds a little less at 0.42 million, or 0.57% of the shares, all valued at about 0.23 million.
